Cagrilintide + Semaglutide | Buy Research-Grade CagriSema in Europe | ≥99% Purity

Cagrilintide + Semaglutide (CagriSema) is a dual amylin analogue and GLP-1 receptor agonist peptide combination, available to buy in Europe for laboratory research into metabolic regulation, appetite and energy homeostasis biology, adiposity mechanisms, and the complementary pharmacology of combined amylin and incretin receptor signalling.

Laboratories and research institutions across the EU can order verified, research-grade Cagrilintide and Semaglutide with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA)

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch to EU & Europe | Tracked Shipping

What is Cagrilintide + Semaglutide (CagriSema)?

Cagrilintide + Semaglutide — referred to in the research literature as CagriSema — is a combination of two distinct synthetic peptide compounds targeting complementary metabolic regulatory pathways: Cagrilintide, a long-acting amylin analogue, and Semaglutide, a GLP-1 receptor agonist. Together they engage two separate but functionally synergistic hormonal systems involved in appetite regulation, gastric emptying, glucose homeostasis, and energy balance — making their combination one of the most actively researched dual-mechanism metabolic peptide combinations in current pre-clinical and clinical investigation.

Cagrilintide is a synthetic long-acting analogue of amylin — the 37 amino acid pancreatic peptide co-secreted with insulin from beta cells in response to nutrient intake. Native amylin acts through amylin receptors (AMY1-3) — which are calcitonin receptor/RAMP complexes — in the area postrema and other brain regions to suppress glucagon secretion, slow gastric emptying, and reduce food intake through satiety signalling. Cagrilintide incorporates fatty acid chain conjugation and amino acid substitutions that confer resistance to enzymatic degradation and enable albumin binding — extending its half-life to approximately one week and providing sustained amylin receptor engagement suitable for research protocols requiring prolonged amylin pathway activation.

Semaglutide is a synthetic GLP-1 receptor agonist — a fatty acid conjugated analogue of glucagon-like peptide-1 (GLP-1), the incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. GLP-1 receptor activation drives insulin secretion, suppresses glucagon release, slows gastric emptying, and — critically — activates hypothalamic and brainstem appetite-suppressing circuits through GLP-1 receptor expression in CNS satiety centres. Semaglutide’s C18 fatty acid conjugation enables albumin binding and protects against DPP-IV degradation — extending its half-life to approximately one week and producing sustained GLP-1R engagement with well-characterised effects on glucose metabolism and appetite regulation.

The combination of these two compounds in CagriSema research targets amylin and GLP-1 receptor pathways simultaneously — pathways that act through distinct but complementary neuronal circuits and peripheral mechanisms to regulate energy homeostasis — producing combined metabolic effects that current research suggests exceed those achievable through either pathway alone.

What Does CagriSema Do in Research?

In laboratory settings, Cagrilintide and Semaglutide are studied individually and in combination, with research applications centred on metabolic regulation, appetite biology, and the pharmacology of combined amylin and GLP-1 receptor signalling. EU and European researchers working with CagriSema typically focus on:

• Dual amylin and GLP-1 receptor pharmacology — the core research application of CagriSema is the simultaneous engagement of amylin receptors and GLP-1 receptors — enabling studies of how complementary incretin and amylin pathway co-activation influences metabolic outcomes beyond single receptor pathway stimulation.
• Appetite regulation and energy homeostasis — both Cagrilintide and Semaglutide engage central nervous system appetite-suppressing circuits — with amylin receptors in the area postrema and nucleus tractus solitarius and GLP-1 receptors in the hypothalamus and brainstem contributing to complementary satiety signalling. Research has examined how co-activation of these circuits produces additive or synergistic reductions in food intake and body weight parameters.
• Obesity and adiposity biology research — pre-clinical studies have used CagriSema to examine effects on adipose tissue mass, body composition parameters, and the metabolic consequences of combined amylin and GLP-1 pathway activation in dietary and genetic obesity models.
• Glucose homeostasis and insulin secretion research — both compounds influence glucose metabolism through complementary mechanisms — Cagrilintide through glucagon suppression and gastric emptying delay, Semaglutide through glucose-dependent insulin secretion enhancement and glucagon suppression — making CagriSema a research tool for studying combined incretin and amylin effects on glycaemic regulation.
• Gastric emptying and gut motility biology — both amylin and GLP-1 receptor activation delay gastric emptying through peripheral and central mechanisms — and CagriSema is used in research examining how combined pathway activation influences gut motility parameters and the contribution of gastric emptying delay to their metabolic effects.
• Hypothalamic appetite circuit research — studies have examined the hypothalamic and brainstem neuronal circuits mediating the appetite-suppressing effects of combined amylin and GLP-1 receptor activation — including effects on POMC/AgRP neuronal activity, arcuate nucleus signalling, and the integration of peripheral satiety signals in CNS energy homeostasis regulation.
• Beta cell biology research — amylin is co-secreted with insulin from pancreatic beta cells, and Cagrilintide’s amylin receptor pharmacology is studied in the context of beta cell biology — including research examining amylin’s role in coordinating post-prandial metabolic responses alongside insulin and the effects of amylin receptor activation on beta cell function parameters.
• Cardiovascular metabolic research — GLP-1 receptor agonism has well-documented cardiovascular biology beyond glycaemic effects, and Semaglutide is studied in cardiovascular metabolic research models alongside its metabolic profile — with CagriSema combination research examining whether amylin co-activation modifies these cardiovascular biology parameters.
• Lipid metabolism and hepatic biology — studies have examined CagriSema effects on lipid metabolism parameters including triglycerides, hepatic lipid accumulation, and fatty acid oxidation in metabolic disease models — characterising the combined influence of amylin and GLP-1 pathway activation on lipid homeostasis.
• Comparative incretin combination pharmacology — CagriSema is studied alongside other dual and triple agonist combinations — including GLP-1/GIP dual agonists and GLP-1/GIP/glucagon triple agonists — as part of the broader research landscape examining combination metabolic peptide pharmacology and the relative contributions of different receptor pathway combinations to metabolic outcomes.

All research applications are for in vitro and pre-clinical use only.

What Do Studies Say About Cagrilintide + Semaglutide?

CagriSema has generated a rapidly growing and high-profile research literature — with pre-clinical studies establishing the pharmacological rationale for combining amylin and GLP-1 receptor pathways, and clinical research programmes documenting the metabolic effects of the combination in human subjects at a scale unusual for research-stage peptide combinations.

Pre-clinical combination pharmacology: Foundational pre-clinical studies examining combined amylin and GLP-1 receptor activation provided the mechanistic rationale for CagriSema — documenting that co-administration of amylin and GLP-1 receptor agonists produces greater reductions in food intake and body weight than either compound alone in rodent models. These findings established the biological basis for the combination approach and characterised the complementary neuronal mechanisms through which the two pathways interact.

Cagrilintide pharmacokinetics and amylin biology: Studies characterising Cagrilintide’s pharmacokinetics documented its extended half-life through fatty acid conjugation and albumin binding — establishing it as a practical long-acting amylin analogue research tool. Research has characterised its amylin receptor engagement profile across AMY1, AMY2, and AMY3 receptor subtypes and its downstream effects on glucagon suppression, gastric emptying, and satiety signalling in pre-clinical models.

Semaglutide GLP-1R pharmacology: Semaglutide has one of the most extensively characterised pharmacological profiles of any GLP-1 receptor agonist — with studies documenting its receptor binding kinetics, downstream cAMP/PKA signalling, effects on insulin secretion, glucagon suppression, gastric emptying delay, and central appetite circuit activation. This established pharmacological foundation provides a well-characterised basis for interpreting the additive effects observed in CagriSema combination research.

Clinical combination research: CagriSema has been examined in Phase II clinical trials — with published findings documenting substantial reductions in body weight and improvements in glycaemic parameters in participants with overweight and type 2 diabetes. These clinical findings have positioned CagriSema among the most effective metabolic peptide combinations studied to date and have driven significant research interest in the amylin/GLP-1 dual pathway approach as a model for studying combined hormonal metabolic regulation.

Synergistic weight reduction findings: Research comparing CagriSema combination effects to Semaglutide monotherapy has documented that the addition of Cagrilintide produces greater reductions in body weight and adiposity than Semaglutide alone — findings interpreted as reflecting additive or synergistic engagement of complementary appetite-suppressing circuits. These findings have been central to establishing the scientific rationale for dual amylin/GLP-1 receptor targeting as a research model for studying combined metabolic hormone pharmacology.

Metabolic parameter characterisation: Studies have characterised CagriSema effects on a comprehensive panel of metabolic parameters — including fasting and post-prandial glucose, HbA1c, insulin sensitivity markers, lipid profiles, and body composition measurements — providing a detailed metabolic pharmacodynamic profile for the combination that has informed ongoing research into combined amylin and incretin pathway biology.

CagriSema vs Related Metabolic Peptide Research Combinations

Compound	Targets	Mechanism	Key Research Distinction
CagriSema (Cagrilintide + Semaglutide)	Amylin receptor + GLP-1R	Dual amylin/incretin pathway	Most advanced dual amylin/GLP-1 combination research
Semaglutide alone	GLP-1R	GLP-1 receptor agonism	Reference GLP-1R agonist — single pathway
Tirzepatide	GLP-1R + GIPR	Dual incretin agonism	GLP-1/GIP dual agonism — distinct combination
Retatrutide	GLP-1R + GIPR + GcgR	Triple agonism	GLP-1/GIP/Glucagon triple pathway research
Pramlintide	Amylin receptor	Short-acting amylin analogue	Reference amylin analogue — single pathway
Liraglutide	GLP-1R	GLP-1 receptor agonism	Earlier GLP-1R agonist — comparative pharmacology

Buying Cagrilintide + Semaglutide in Europe — What’s Included

Every order of Cagrilintide + Semaglutide dispatched to EU and European research institutions includes:

• Batch-Specific Certificate of Analysis (CoA) for each compound
• HPLC Chromatogram
• Mass Spectrometry Confirmation
• Sterility and Endotoxin Testing Reports
• Reconstitution Protocol
• Technical Research Support

Frequently Asked Questions — CagriSema EU

Can I Buy Cagrilintide and Semaglutide in the EU and Europe?

Yes. We supply research-grade Cagrilintide and Semaglutide with fast tracked international dispatch to all EU member states and wider European destinations including Germany, France, Netherlands, Spain, Italy, Poland, and beyond. Each compound is supplied with full batch documentation and packaging designed to maintain peptide integrity throughout transit. Both compounds are supplied strictly for laboratory research use only.

What is Amylin and How Does Cagrilintide Relate to It?

Amylin is a 37 amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to food intake. It acts through amylin receptors — complexes formed by calcitonin receptors paired with receptor activity modifying proteins (RAMPs) — in the area postrema, nucleus tractus solitarius, and other brain regions to suppress glucagon secretion, slow gastric emptying, and signal satiety. Native amylin has a very short half-life and limited research utility in extended protocols. Cagrilintide is a long-acting synthetic amylin analogue incorporating amino acid substitutions and fatty acid conjugation that confer enzymatic stability and albumin binding — extending its half-life to approximately one week and providing sustained amylin receptor engagement for pre-clinical research.

What is the Difference Between Semaglutide and Liraglutide in Research?

Semaglutide and Liraglutide are both GLP-1 receptor agonists but differ in their structural modifications, half-lives, and potency profiles. Liraglutide uses a C16 fatty acid conjugation for albumin binding — producing a half-life of approximately 13 hours. Semaglutide uses a C18 fatty acid conjugation via a linker with additional backbone modifications — producing a half-life of approximately one week and substantially greater GLP-1R potency per unit dose. Semaglutide’s extended half-life makes it the preferred compound for CagriSema combination research — matching the pharmacokinetic profile of long-acting Cagrilintide and enabling once-weekly dosing protocols in pre-clinical research designs.

Why Do Amylin and GLP-1 Receptor Pathways Complement Each Other in Metabolic Research?

Amylin and GLP-1 act through distinct receptor systems and neuronal circuits to regulate energy homeostasis — with amylin receptors concentrated in the area postrema and brainstem, and GLP-1 receptors expressed in the hypothalamus, brainstem, and peripheral tissues. Despite their distinct receptor biology, both pathways converge on appetite suppression and metabolic regulation through complementary mechanisms — amylin primarily through glucagon suppression, gastric emptying delay, and brainstem satiety signalling, GLP-1 through insulin secretion enhancement, glucagon suppression, and hypothalamic appetite circuit activation. Research has documented that co-activation of both pathways produces metabolic effects exceeding either pathway alone — a finding that has established the dual amylin/GLP-1 combination as a high-interest research model for studying complementary hormonal metabolic regulation.

What is the Difference Between CagriSema and Tirzepatide in Metabolic Research?

CagriSema and Tirzepatide represent two distinct dual-mechanism approaches to metabolic peptide pharmacology. Tirzepatide is a dual GLP-1R/GIPR agonist — combining GLP-1 and GIP receptor activation in a single molecule, engaging two incretin pathways simultaneously. CagriSema combines amylin receptor activation via Cagrilintide with GLP-1R activation via Semaglutide — engaging the amylin pathway alongside the incretin pathway. The two combinations target overlapping but distinct receptor biology and neuronal circuits, and are studied as complementary research models for examining how different combinations of metabolic hormone receptor activation influence energy homeostasis and metabolic parameters.

How Are Cagrilintide and Semaglutide Reconstituted for Laboratory Use?

Allow each vial to reach room temperature before opening. Add sterile water or an appropriate laboratory buffer slowly down the vial wall and swirl gently — do not shake. Both compounds are fatty acid conjugated peptides — prepare stock solutions at your protocol’s required concentration, aliquot, and store at -80°C to minimise freeze-thaw degradation. For combination research protocols, reconstitute each compound separately and combine at the required ratio in the experimental preparation. Standard peptide handling protocols apply for both compounds.

How Quickly is CagriSema Delivered to Europe?

Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to protect peptide stability throughout transit.

Product Specifications

Parameter	Cagrilintide	Semaglutide
Type	Long-acting amylin analogue	GLP-1 receptor agonist
Origin	Synthetic amylin analogue	Synthetic GLP-1 analogue
Modification	Fatty acid conjugation, amino acid substitutions	C18 fatty acid conjugation, backbone modification
Primary Target	Amylin receptors (AMY1-3)	GLP-1 receptor (GLP-1R)
Half-Life	~1 week	~1 week
Primary Research Interest	Amylin pharmacology, appetite, glucose regulation	GLP-1R pharmacology, incretin biology, metabolic regulation
Purity	≥99%	≥99%
Verification	HPLC & Mass Spectrometry	HPLC & Mass Spectrometry
Form	Sterile Lyophilised Powder	Sterile Lyophilised Powder
Storage	-20°C, protected from light	-20°C, protected from light
Intended Use	Research use only	Research use only

Research Disclaimer

Cagrilintide and Semaglutide are supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. These products are not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. They must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm these compounds will be used exclusively for approved in vitro or pre-clinical research purposes.